Anti-Psychotic Drugs Market Is Driven By the Increasing Prevalence of Mental Disorders

Anti-psychotic drugs, also called neuroleptics or tranquilizers, are widely used for the treatment of bipolar disorder or schizophrenia. According to the World Health Organization’s (WHO) 2019 report, schizophrenia is a chronic/severe mental disorder that affects around 20 million people around the world. Therefore, with the increasing prevalence of mental disorders, such as schizophrenia, the demand for anti-psychotic drugs is also increasing with a rapid pace.

Request Here Sample Report:
https://www.coherentmarketinsights.com/insight/request-sample/1196

For example, in April 2018, Otsuka Pharmaceutical Co., Ltd. announced the launch of a new antipsychotic drugs, REXULTI Tablets (1 mg and 2 mg tablets), in Japan for the treatment of schizophrenia. REXULTI is available in the United States, Canada, and Australia. This in turn is expected to accelerate the growth of the anti-psychotic drugs market.

Anti-psychotic drugs is a category of psychotropic drugs mainly used to treat psychosis, mainly in schizophrenia, but also in an increasing number of other psychotic diseases. They are still the mainstay of treatment for bipolar disorder, along with mood stabilizers. These drugs can effectively block many of the chemicals and neurons that are responsible for hallucinations and delusions, as well as the ability of the brain to care and recognize reality. Thus, there is high demand for these drugs in the market, driving the anti-psychotic drugs market.

The most commonly used anti-psychotic drugs are clozapine (Clozaril), asenapine (Saphris), quetiapine (Seroquel), olanzapine (Zyprexa), cariprazine (Vraylar), aripiprazole (Abilify), lurasidone (Latuda), and risperidone (Risperdal). Some research suggests that there is a higher effectiveness of these drugs in the short term than in the long term and that patients become tolerant to them faster.

Long-term use of these anti-psychotic medications has been associated with the development of conditions such as depression, mania, psychosis, mania, and mixed disorders, which often require hospitalization. This in turn is expected to restrain the growth of the anti-psychotic drugs market.

𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐨𝐟𝐟𝐞𝐫!!! 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐚 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐫𝐚𝐭𝐞!!!

𝐅𝐥𝐚𝐭 𝐈𝐧𝐬𝐭𝐚𝐧𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐟 𝐔𝐒$ 𝟐𝟎𝟎𝟎

𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐀 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.coherentMarketinsights.com/promo/buynow/1196

Major Market Competitors: AstraZeneca, Pfizer, Inc., Eli Lily and Co., Bristol- Myers Squibb, Johnson & Johnson, GlaxoSmithKline, and Allergen.

𝐅𝐫𝐞𝐪𝐮𝐞𝐧𝐭𝐥𝐲 𝐀𝐬𝐤𝐞𝐝 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬?

𝐖𝐡𝐚𝐭 𝐰𝐢𝐥𝐥 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐛𝐞 𝐢𝐧 𝟐𝟎𝟐𝟕?

𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐤𝐞𝐲 𝐟𝐚𝐜𝐭𝐨𝐫𝐬 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐦𝐚𝐫𝐤𝐞𝐭?

𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐭𝐨 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡?

𝐖𝐡𝐨 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐤𝐞𝐲 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭?

𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐚𝐧𝐝 𝐭𝐡𝐫𝐞𝐚𝐭𝐬 𝐟𝐚𝐜𝐞𝐝 𝐛𝐲 𝐭𝐡𝐞 𝐤𝐞𝐲 𝐩𝐥𝐚𝐲𝐞𝐫𝐬?

𝐖𝐡𝐚𝐭 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐭𝐡𝐞 𝐠𝐫𝐨𝐰𝐭𝐡 𝐫𝐚𝐭𝐞 𝐢𝐧 𝟐𝟎𝟐𝟕?

𝐖𝐡𝐢𝐜𝐡 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐚𝐫𝐞 𝐮𝐬𝐞𝐝 𝐛𝐲 𝐭𝐨𝐩 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐊𝐤𝐤 𝐌𝐚𝐫𝐤𝐞𝐭?

Download PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1196

Have a Look at Related Research Insights:

https://www.medgadget.com/2021/07/stomach-cancer-drugs-market-size-is-anticipated-to-reach-us-6-6-billion-at-a-cagr-of-5-4-by-2026-share-analysis-future-insights-growth-estimation-and-industry-trends.html

https://www.medgadget.com/2021/07/postpartum-depression-drug-market-potential-growth-current-scenario-size-share-prominent-players-demand-and-trends-cmi-unleashes-the-forecast-to-2027.html

Contact us:
Mr. Shah
Senior Client Partner – Business Development
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
sales@coherentMarketinsights.com

𝗔𝗯𝗼𝘂𝘁 𝗖𝗼𝗵𝗲𝗿𝗲𝗻𝘁 𝗠𝗮𝗿𝗸𝗲𝘁 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀:-
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunities.

This release was published on openPR.